Inhibiting MEK in MAPK pathway-activated myeloma

被引：79

作者：

Heuck, C. J. ^{[1
]}

Jethava, Y. ^{[1
]}

Khan, R. ^{[1
]}

van Rhee, F. ^{[1
]}

Zangari, M. ^{[1
]}

Chavan, S. ^{[1
]}

Robbins, K. ^{[1
]}

Miller, S. E. ^{[1
]}

Matin, A. ^{[1
]}

Mohan, M. ^{[1
]}

Ali, S. M. ^{[2
]}

Stephens, P. J. ^{[2
]}

Ross, J. S. ^{[2
,3
]}

Miller, V. A. ^{[2
]}

Davies, F. ^{[1
]}

Barlogie, B. ^{[1
]}

Morgan, G. ^{[1
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA

[2] Fdn Med Inc, Cambridge, MA USA

[3] Albany Med Coll, Dept Pathol, Albany, NY 12208 USA

来源：

LEUKEMIA | 2016年 / 30卷 / 04期

关键词：

MULTIPLE-MYELOMA; TOTAL THERAPY; WILD-TYPE; HETEROGENEITY; BORTEZOMIB; RISK; RAF;

D O I：

10.1038/leu.2015.208

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：976 / 980

页数：6

共 15 条

[11] RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth [J].

Hatzivassiliou, Georgia ;

Song, Kyung ;

Yen, Ivana ;

Brandhuber, Barbara J. ;

Anderson, Daniel J. ;

Alvarado, Ryan ;

Ludlam, Mary J. C. ;

Stokoe, David ;

Gloor, Susan L. ;

Vigers, Guy ;

Morales, Tony ;

Aliagas, Ignacio ;

Liu, Bonnie ;

Sideris, Steve ;

Hoeflich, Klaus P. ;

Jaiswal, Bijay S. ;

Seshagiri, Somasekar ;

Koeppen, Hartmut ;

Belvin, Marcia ;

Friedman, Lori S. ;

Malek, Shiva .

NATURE, 2010, 464 (7287) :431-U132

[12] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].

Kumar, S. K. ;

Lee, J. H. ;

Lahuerta, J. J. ;

Morgan, G. ;

Richardson, P. G. ;

Crowley, J. ;

Haessler, J. ;

Feather, J. ;

Hoering, A. ;

Moreau, P. ;

LeLeu, X. ;

Hulin, C. ;

Klein, S. K. ;

Sonneveld, P. ;

Siegel, D. ;

Blade, J. ;

Goldschmidt, H. ;

Jagannath, S. ;

Miguel, J. S. ;

Orlowski, R. ;

Palumbo, A. ;

Sezer, O. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2012, 26 (01) :149-157

[13] Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy [J].

Lohr, Jens G. ;

Stojanov, Petar ;

Carter, Scott L. ;

Cruz-Gordillo, Peter ;

Lawrence, Michael S. ;

Auclair, Daniel ;

Sougnez, Carrie ;

Knoechel, Birgit ;

Gould, Joshua ;

Saksena, Gordon ;

Cibulskis, Kristian ;

McKenna, Aaron ;

Chapman, Michael A. ;

Straussman, Ravid ;

Levy, Joan ;

Perkins, Louise M. ;

Keats, Jonathan J. ;

Schumacher, Steven E. ;

Rosenberg, Mara ;

Getz, Gad ;

Golub, Todd R. .

CANCER CELL, 2014, 25 (01) :91-101

[14] A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1 [J].

Shaughnessy, John D. ;

Zhan, Fenghuang ;

Burington, Bart E. ;

Huang, Yongsheng ;

Colla, Simona ;

Hanamura, Ichiro ;

Stewart, James P. ;

Kordsmeier, Bob ;

Randolph, Christopher ;

Williams, David R. ;

Xiao, Yan ;

Xu, Hongwei ;

Epstein, Joshua ;

Anaissie, Elias ;

Krishna, Somashekar G. ;

Cottler-Fox, Michele ;

Hollmig, Klaus ;

Mohiuddin, Abid ;

Pineda-Roman, Mauricio ;

Tricot, Guido ;

van Rhee, Frits ;

Sawyer, Jeffrey ;

Alsayed, Yazan ;

Walker, Ronald ;

Zangari, Maurizio ;

Crowley, John ;

Barlogie, Bart .

BLOOD, 2007, 109 (06) :2276-2284

[15] Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms [J].

Walker, B. A. ;

Wardell, C. P. ;

Melchor, L. ;

Brioli, A. ;

Johnson, D. C. ;

Kaiser, M. F. ;

Mirabella, F. ;

Lopez-Corral, L. ;

Humphray, S. ;

Murray, L. ;

Ross, M. ;

Bentley, D. ;

Gutierrez, N. C. ;

Garcia-Sanz, R. ;

Miguel, J. San ;

Davies, F. E. ;

Gonzalez, D. ;

Morgan, G. J. .

LEUKEMIA, 2014, 28 (02) :384-390

← 1 2 →